Work

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

Year: 2012

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-12-1158

Authors: John Moroney, Siqing Fu, Stacy Moulder, Gerald Falchook, Thorunn Helgason, Charles Levenback, David Hong, Aung Naing, Jennifer Wheler, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, Wright-Patterson Air Force Base

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, U.S. Food and Drug Administration, University of Texas MD Anderson Cancer Center, National Center for Research Resources

Awards: G1826404230, Center for Clinical and Translational Sciences

OpenAlex ID: W2152875417

FWCI: 4.889

Cites: 36

Cited by: 88

Related to: 10